| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In MEF cells, deferoxamine (1 mM; 16 hours or 4 weeks) lowers ROS and enhances HIF-1α function in hypoxic and hyperglycemic environments [1]. Deferoxamine (100 µM; 24 hours) raises the levels of p-Akt/total Akt/PKB and enhances the expression and activity of InsR [2]. Both bone marrow MSCs and tumor-associated MSCs are inhibited in their ability to proliferate by defremoxiamine (5, 10, 25, 50, 100 µM; 7 or 9 days). MSC apoptosis is induced by defremoxamine (5, 10, 25, 50, and 100 µM; 7 days) [3]. On MSCs, deferoxamine (10 µM; 3 days) had an impact on adhesion protein expression [3]. In SH-SY5Y cells, deferoxamine (100 µM; 24 hours) promotes autophagy mediated by HIF-1α levels [4].
|
|---|---|
| ln Vivo |
In aged or diabetic mice, deferoxamine (560.68 mg/tube; infusion; once daily for 21 days) improves wound healing and increases neovascularization [1]. In vivo, deferoxamine (200 mg/kg; i.p.; once daily for two weeks) boosts glucose uptake, hepatic InsR expression, and signaling while stabilizing HIF-1α [2].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: MEFs Cell Tested Concentrations: 1 mM Incubation Duration: 16 hrs (hours) (hypoxic conditions); 4 weeks (hyperglycemic conditions) Experimental Results: Under hypoxic and high glucose conditions, Dramatically attenuated hyperglycemia-related The ROS levels increase. Normoxia HIF transactivation is Dramatically increased in MEFs under both high- and normoglycemic conditions. Western Blot Analysis[2] Cell Types: HepG2 Cell Tested Concentrations: 100 µM Incubation Duration: 24 hrs (hours) Experimental Results: Twofold increase in InsR mRNA levels in cells. At the half-maximal concentration of 1.1 nM, InsR binding activity increased twofold. Cell proliferation assay[3] Cell Types: TAMSC and BMMSC (all isolated from male C57BL/6J mice (8 weeks old; EG-7 induced tumor model)) Tested Concentrations: 5, 10, 25, 50, 100 µM Incubation Duration: 7 days (TAMSC); 9 days (BMMSC). Experimental Results: At doses of 50 and 100 μM, the growth of TAMSC and BMMSC was inhibited, and most cells died on day 7 or 9. Apoptosis analysis [3] Cell Types: TAMSCs, |
| Animal Protocol |
Animal/Disease Models: Aged (21 months old) and diabetic (12 weeks old) C57BL/6J mice (excision wound model) [1].
Doses: 560.68 mg/each (10 uL, 1 mM) Route of Administration: Infusion; one time/day for 21 days. Experimental Results: Demonstrated Dramatically accelerated healing and increased neovascularization in aged and diabetic mouse models. Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat (180-200 g) [2]. Doses: 200 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day for 2 weeks. Experimental Results: The liver HIF-1α protein level was Dramatically increased, and the InsR protein level, Akt/PKB and activated Akt/PKB in the liver were Dramatically increased. |
| References |
[1]. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e.
[2]. Dongiovanni P, et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008 Mar;172(3):738-47. [3]. Wang G, et al. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64. [4]. Wu Y, et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct;57(3):198-205. [5]. Bellotti D, et al. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules. 2021 May 28;26(11):3255. |
| Molecular Formula |
C25H48N6O8
|
|---|---|
| Molecular Weight |
560.68402
|
| CAS # |
70-51-9
|
| Related CAS # |
Deferoxamine mesylate;138-14-7
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
CC(N(O)CCCCCNC(CCC(N(O)CCCCCNC(CCC(N(O)CCCCCN)=O)=O)=O)=O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~22.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.23 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7835 mL | 8.9177 mL | 17.8355 mL | |
| 5 mM | 0.3567 mL | 1.7835 mL | 3.5671 mL | |
| 10 mM | 0.1784 mL | 0.8918 mL | 1.7835 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
